Bupropion

@article{Dhillon2012Bupropion,  title={Bupropion},  author={Sohita Dhillon and Lily P. H. Yang and Monique P. Curran},  journal={Drugs},  year={2012},  volume={68},  pages={653-689},  url={https://api.semanticscholar.org/CorpusID:195687060}}
Available clinical data suggest that bupropion is an effective and generally well tolerated option in the treatment of MDD, with the newer formulations having the advantage of reduced frequency of daily administration.

125 Citations

Spotlight on Bupropion in Major Depressive Disorder

Clinical data suggest that bupropion is an effective and generally well tolerated option in the treatment of MDD, with the newer formulations having the advantage of reduced frequency of daily administration.

The Role of Bupropion in the Management of Major Depressive Disorder

Bupropion has been used in the treatment of geriatric depression with good therapeutic efficacy and health outcome measurements and has also shown usefulness as a smoking cessation agent and in treating depression in patients with medical co-morbidities such as asthma and HIV.

Drug safety evaluation of naltrexone/bupropion for the treatment of obesity

Naltrexone/bupropion has a greater weight loss efficacy than two FDA-approved medications, orlistat and lorcaserin and phentermine/topiramate, and has no abuse potential.

From dual action compounds to triple reuptake inhibitors: considerations on the development of a new class of antidepressants

The recent development of triple reuptake inhibitors in the treatment of Major Depression seems to be the natural consequence of the evolution of the most recent classes of antidepressants in order to realize compounds that conjugate a wide spectrum of action with selectivity and specificity.

Bupropion Mediated Effects on Depression, Attention Deficit Hyperactivity Disorder, and Smoking Cessation.

Bupropion has the potential to provide benefit for a subset of patients who do not tolerate other typical antidepressants or anti-smoking therapies or for those whose treatment goals align with bupropion's unique side effect profile, such as smokers who wish to quit and lose weight.

The Efficacy and Tolerability of Bupropion in the Treatment of Major Depressive Disorder

Bupropion is approved for the treatment ofMDD in the USA, Canada and many countries in Europe, and current evidence-based guidelines reinforce its place as an efficacious and well-tolerated treatment option in the pharmacological management of MDD.
...

61 References

Bupropion-SR, sertraline, or venlafaxine-XR after failure of SSRIs for depression.

After unsuccessful treatment with an SSRI, approximately one in four patients had a remission of symptoms after switching to another antidepressant, suggesting any one of the medications in the study provided a reasonable second-step choice for patients with depression.

Double-blind comparison of bupropion sustained release and sertraline in depressed outpatients.

Both compounds were relatively well tolerated, and orgasm dysfunction, nausea, diarrhea, somnolence, and sweating were reported more frequently in sertraline-treated patients.

Do bupropion SR and sertraline differ in their effects on anxiety in depressed patients?

Bupropion SR and sertraline had comparable antidepressant and anxiolytic effects and an equally rapid onset of clinically significant anxio-lytic activity.

A Review of the Neuropharmacology of Bupropion, a Dual Norepinephrine and Dopamine Reuptake Inhibitor.

The preclinical and clinical data show that bupropion acts via dual inhibition of norepinephrine and dopamine reuptake and is devoid of clinically significant serotonergic effects or direct effects on postsynaptic receptors.

Pharmacokinetic Optimisation of Sustained-Release Bupropion for Smoking Cessation

Sustained-release bupropion (bupropion SR) is a unique, non-nicotine smoking cessation aid that is hypothesised to act upon neurological pathways involved in nicotine dependence. Pharmacokinetic and…

Bupropion sustained release versus paroxetine for the treatment of depression in the elderly.

Because of its favorable side effect profile, bupropion SR may provide a safe and effective nonserotonergic treatment alternative that is well suited as an antidepressant for the elderly.

15 years of clinical experience with bupropion HCl: from bupropion to bupropion SR to bupropion XL.

Bupropion has played and will continue to play an important role as a treatment for major depressive disorder in adults, as well as for other related disorders.

Bupropion occupancy of the dopamine transporter is low during clinical treatment

Bupropion treatment occupies less than 22% of DAT sites, which raises the question as to whether a DAT occupancy of less than22% is therapeutic or whether there is another mechanism involved during treatment with bupropion.
...

Related Papers

Showing 1 through 3 of 0 Related Papers